2026 Forecast: New GLP-1 Drugs, Trends, and What to Expect This Year

By GLPeak Team · 2026-01-04

From CagriSema to Retatrutide, oral pills to muscle preservation—here's your complete guide to what's coming in the GLP-1 space in 2026.

If 2024 was the year the world discovered GLP-1s, and 2025 was the year of shortages and supply wars, 2026 is shaping up to be the year of "Optimization."

We are moving past the "does it work?" phase (we know they do). Now, the conversation is shifting to nuance: preserving muscle, personalizing doses, and finding new options. The "one-size-fits-all" era of weight loss is officially over.

Here is your roadmap for what to expect in the GLP-1 space in 2026.

1. The Next Wave of Injectables

Current options like Wegovy and Zepbound are excellent, but two major injectable contenders are nearing the finish line this year.

CagriSema (Novo Nordisk)

The Gist: A combination of Semaglutide (Wegovy) and a new amylin analogue called Cagrilintide. Think of it as "Wegovy Plus."

The Status: After mixed but promising Phase 3 data in late 2025, Novo Nordisk is expected to file for FDA approval in Q1 of this year.

Why it matters: In trials, it demonstrated weight loss potential that rivals Zepbound (tirzepatide), but with a different mechanism that might break plateaus for non-responders.

Retatrutide (Eli Lilly)

The Gist: If Ozempic hits one receptor and Zepbound hits two, Retatrutide hits three: GLP-1, GIP, and Glucagon.

Why Watch It: Adding that third mechanism seems to rev up resting energy expenditure (your metabolism) in a way the others don't. The early data showed weight loss numbers approaching 25–29%, which is basically unheard of outside of surgery.

Timeline: Phase 3 trials are still running, but we expect significant data updates this year.

2. The Battle for Muscle Mass

The biggest conversation trend for 2026 isn't just about losing weight, but what kind of weight you are losing.

With widespread reports of "Ozempic Face" and sarcopenia (muscle loss) in 2025, the industry is pivoting hard toward muscle preservation.

New Combinations: Watch for clinical trials launching this year that combine GLP-1s with muscle-sparing agents (like bimagrumab or similar myostatin inhibitors).

The Shift in Guidance: Expect your doctor (and GLPeak coaches) to talk less about BMI and more about Body Composition Scans (DEXA). The goal for 2026 is "High-Quality Weight Loss"—burning fat while protecting lean tissue.

3. Oral Competition Heats Up

The launch of Oral Wegovy this month is just the start.

Orforglipron (Eli Lilly): Unlike the Wegovy pill, which must be taken with strict fasting rules, Lilly's experimental daily pill is a "non-peptide" small molecule. This means it might be easier to absorb and have fewer dietary restrictions. Phase 3 results are expected early this year. If the data is good, the "strict morning routine" of current oral GLP-1s could become obsolete by 2027.

4. New "Non-Scale" Victories (and Defeats)

The science is expanding into new territories.

The Good (Sleep & Heart): Following the 2025 approval of Zepbound for sleep apnea, we expect more data this year on how these drugs affect kidney disease and liver health (MASH).

The Bad (Alzheimer's): Late 2025 brought disappointing news that semaglutide failed to significantly slow Alzheimer's progression in the EVOKE trials. While the drugs are miracles for metabolism, 2026 will likely be the year we learn the limits of what they can't do.

5. Supply Chain Stabilization

Finally, a bit of boring but good news: The supply chain seems to have stabilized. With massive new manufacturing sites online in North Carolina and Europe, the "Hunger Games" vibe of trying to find a starter dose is largely behind us. The challenge for 2026 won't be finding the drug. It will be navigating insurance coverage as payers tighten their criteria.

With new pills, next-gen shots, and strict dosing protocols, the landscape is getting more complicated. Understanding your own data is more valuable than ever. GLPeak is updated for 2026 to give you clarity. By visualizing your doses alongside weight, mood, and energy trends, the app gives you a clear, objective view of how your body is responding, removing the guesswork from your journey.

Disclaimer: This blog is for informational purposes only and does not constitute medical advice. New drugs mentioned (Retatrutide, CagriSema) are investigational and not yet FDA-approved as of Jan 2026.

Sources & Further Reading:

Open GLPeak →